Page last updated: 2024-12-08

n-acetyl-5-methoxy kynurenamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-acetyl-5-methoxy kynurenamine: melatonin brain metabolite [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID390658
CHEMBL ID369941
CHEBI ID173696
SCHEMBL ID20556223
MeSH IDM0100451

Synonyms (26)

Synonym
n-acetyl-5-methoxykynurenamine
acetamide, n-(3-(2-amino-5-methoxyphenyl)-3-oxopropyl)-
n(gamma)-acetyl-5-methoxykynurenamine
n-[3-(2-amino-5-methoxyphenyl]-3-oxopropyl]acetamide
n-[3-(2-amino-5-methoxyphenyl)-3-oxopropyl]acetamide
CHEBI:173696
52450-39-2
n-acetyl-5-methoxykynuramine
nsc688265
NCI60_031862
amka
nsc-688265
CHEMBL369941
kinurenamine
yy9b6v6wk3 ,
unii-yy9b6v6wk3
amk kynuramine cpd
n-acetyl-5-methoxy kynurenamine
n(1)-acetyl-5-methoxykynuramine
acetamide, n-[3-(2-amino-5-methoxyphenyl)-3-oxopropyl]-
SCHEMBL20556223
DTXSID10966880
n-[3-(2-amino-5-methoxyphenyl)-3-oxopropyl]ethanimidic acid
n1-acetyl-5-methoxykynuramine
n-(3-(2-amino-5-methoxyphenyl)-3-oxopropyl)acetamide
n.gamma.-acetyl-5-methoxykynurenamine

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Melatonin and AMK (10(-11)-10(-3) m), but not AFMK, inhibited nNOS activity in vitro in a dose-response manner."( Inhibition of neuronal nitric oxide synthase activity by N1-acetyl-5-methoxykynuramine, a brain metabolite of melatonin.
Acuña-Castroviejo, D; Camacho, E; Carrión, MD; Entrena, A; Escames, G; Espinosa, A; Gallo, MA; León, J; López, LC; Reiter, RJ; Rodríguez, MI; Tan, DX; Tapias, V, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
kynurenamines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
superpathway of tryptophan utilization4292
superpathway of melatonin degradation526
melatonin degradation III17

Bioassays (3)

Assay IDTitleYearJournalArticle
AID256694Percentage inhibition of rat striatal kynurenine 3-hydroxylase (KYN3OH) activity at 1 mM by quantifying 3-hydroxykynurenine production2005Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26
Kynurenamines as neural nitric oxide synthase inhibitors.
AID420682Inhibition of nNOS2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Phenylpyrrole derivatives as neural and inducible nitric oxide synthase (nNOS and iNOS) inhibitors.
AID256693Percentage inhibition of rat striatal neural nitric oxide synthase (nNOS) activity at 1 mM by quantifying L-[3H]citrulline production2005Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26
Kynurenamines as neural nitric oxide synthase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (7.14)18.7374
1990's0 (0.00)18.2507
2000's18 (64.29)29.6817
2010's6 (21.43)24.3611
2020's2 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.91 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (17.86%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (82.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]